Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell TherapyPRNewsWire • 10/04/23
Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual MeetingPRNewsWire • 09/27/23
Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?Seeking Alpha • 09/15/23
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHOPRNewsWire • 09/07/23
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual MeetingPRNewsWire • 08/31/23
NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)Business Wire • 08/29/23
Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 CongressPRNewsWire • 08/21/23
Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals SummitPRNewsWire • 07/24/23
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)Business Wire • 06/27/23
SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA DataPRNewsWire • 06/26/23
PanTera and TerraPower Isotopes join forces to accelerate access to actinium-225GlobeNewsWire • 06/26/23
Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual MeetingPRNewsWire • 06/23/23
Actinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation SummitPRNewsWire • 06/14/23
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 CongressPRNewsWire • 06/12/23
RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine TumorsBusiness Wire • 05/31/23
Actinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Solid CancersPRNewsWire • 05/22/23
Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)PRNewsWire • 05/11/23
Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals DayPRNewsWire • 05/10/23
Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Pivotal Phase 3 SIERRA Trial at the 48th Annual Oncology NPRNewsWire • 04/28/23
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual MeetingPRNewsWire • 04/27/23
Actinium Announces Positive Phase 3 Trial Results, NCI CRADA For AML Drug Candidates – Could They Become New Standards Of Care For This Deadly Disease?Accesswire • 04/21/23
Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual MeetingPRNewsWire • 04/19/23
Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual MeetingPRNewsWire • 04/19/23
